Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML.
Branford S, Fernandes A, Shahrin N, Maqsood M, Shanmuganathan N, Wadham C. Branford S, et al. Among authors: shanmuganathan n. J Natl Compr Canc Netw. 2024 Feb;22(1):e237335. doi: 10.6004/jnccn.2023.7335. J Natl Compr Canc Netw. 2024. PMID: 38394774 Review.
Accelerated-phase CML: de novo and transformed.
Shanmuganathan N, Hughes TP. Shanmuganathan N, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):459-468. doi: 10.1182/hematology.2023000446. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066863
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Shanmuganathan N, Wadham C, Shahrin N, Feng J, Thomson D, Wang P, Saunders V, Kok CH, King RM, Kenyon RR, Lin M, Pagani IS, Ross DM, Yong ASM, Grigg AP, Mills AK, Schwarer AP, Braley J, Altamura H, Yeung DT, Scott HS, Schreiber AW, Hughes TP, Branford S. Shanmuganathan N, et al. Haematologica. 2023 Sep 1;108(9):2380-2395. doi: 10.3324/haematol.2022.282184. Haematologica. 2023. PMID: 36951160 Free PMC article.
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Gómez-García de Soria V, le Coutre P, Mahon FX, Janssen JJWM, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F. Mauro MJ, et al. Among authors: shanmuganathan n. Leukemia. 2023 May;37(5):1048-1059. doi: 10.1038/s41375-023-01860-w. Epub 2023 Mar 22. Leukemia. 2023. PMID: 36949155 Free PMC article. Clinical Trial.
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. Hiwase D, et al. Among authors: shanmuganathan n. Blood. 2023 Mar 2;141(9):1087-1091. doi: 10.1182/blood.2022018236. Blood. 2023. PMID: 36574363 Free article. No abstract available.
Management of TKI-resistant chronic phase CML.
Hughes TP, Shanmuganathan N. Hughes TP, et al. Among authors: shanmuganathan n. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):129-137. doi: 10.1182/hematology.2022000328. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485117 Free PMC article. Review.
44 results